ITGAD (CD11d/Integrin Alpha D) Drug Discovery Landscape & Assay Solutions
- By admin
- 17 Sep 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Chronic Inflammation, Spinal Cord Injury, and Atherosclerosis Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ITGAD (CD11d) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGAD (CD11d) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View ITGAD Products |
| Gene Delivery | ITGAD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for preserving native heterodimeric conformation. |
View ITGAD Products |
| Benchmark Ab | Anti-ITGAD Recombinant Antibody Recombinant positive control derived from benchmark clones (e.g., clone 1B7). |
View ITGAD Products |
| Validator | ITGAD siRNA Set For knockdown verification in macrophage functional assays. |
View ITGAD Products |
| Related Target A | ITGB2 (CD18) The obligate beta-subunit partner. ITGAD must heterodimerize with ITGB2 to form functional Integrin alpha-D/beta-2. |
View ITGB2 Products |
| Related Target B | VCAM1 (CD106) Primary endothelial ligand for ITGAD/CD18, mediating leukocyte adhesion during chronic inflammation. |
View VCAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (Heterodimerization) | Co-expression systems and Lentiviral vectors for stable ITGAD/ITGB2 cell-line generation. |
| Cross-species reactivity validation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ITGAD ortholog proteins available with >95% purity. |
| Lack of Controls | Pre-formulated Clinical Benchmark Biosimilar Antibodies included in the catalog. |
| Off-target assay noise (other Beta-2 Integrins) | High-purity ITGAL (CD11a), ITGAM (CD11b), and ITGAX (CD11c) counter-screening panels. |
Live ITGAD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ITGAD (CD11d) is gaining traction as a highly selective approach to modulate chronic inflammation without causing systemic immunosuppression. Unlike more widely expressed integrins, ITGAD expression is restricted primarily to splenic red pulp macrophages, foam cells in atherosclerotic plaques, and neutrophils at injury sites. The race for ITGAD therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to tissue-targeted monoclonal antibodies and small-molecule integrin antagonists. As first-generation therapies for spinal cord injury (SCI) and neuropathic pain reach clinical milestones, the next wave of R&D is targeting cardiometabolic diseases and neurodegenerative disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Consortia, Bio-Pharma Startups | Spinal Cord Injury, Traumatic Brain Injury | Epitope mapping & cross-species binding assays (Requires high-purity ECD-Fc) |
| Small Molecule Antagonist | Medicinal Chemistry Innovators | Atherosclerosis, NASH, Chronic Inflammatory Pain | High-throughput cell adhesion assays (Requires ITGAD/ITGB2 stable cell lines via Lentivirus) |
| siRNA / RNAi Therapeutics | RNA Therapeutics Specialists | Obesity-Induced Insulin Resistance | In vitro knockdown validation (Requires sequence-verified siRNA sets) |